Clin Asst Prof Chua Lee Min Kevin

Dr Kevin Chua is a Senior Consultant in Radiation Oncology at the National Cancer Centre Singapore and Clinical Assistant Professor at Duke-NUS Medical School. He specialises in thoracic oncology and central nervous system malignancies, with particular expertise in stereotactic radiotherapy, reirradiation and proton therapy.

His research investigates the molecular mechanisms of radioresistance in locally advanced non-small cell lung cancer, with broader interests in biomarker discovery and interactions between radiotherapy and the immune system. This work has received peer-reviewed national grant funding. He has published in journals including CA: A Cancer Journal for Clinicians, The Lancet Oncology, JAMA Oncology, Cancer Discovery and the Journal of Thoracic Oncology, and has contributed to clinical practice recommendations in locally advanced lung cancer, radiation pneumonitis, reirradiation and molecular testing.

Dr Chua is a founding board member of the Singapore Society of Neuro-Oncology and has served on regional and international oncology committees, including the ASCO Asia-Pacific Regional Council, the Asian Society for Neuro-Oncology and the IASLC Global Multidisciplinary Practice Standards Committee. He chairs the Lung Cancer Education Programme Committee for the 2027 ASCO Annual Meeting and the Locoregional NSCLC Programme Track for the 2026 World Conference on Lung Cancer.

• ASCO Leadership Development Program for the Asia-Pacific Region, 2023-2024
• Fellow of the Royal College of Radiologists, FRCR (Clinical Oncology), United Kingdom, 2014
• Honorary Clinical Fellow, Division of Clinical Oncology, University College London and National Hospital for Neurology and Neurosurgery, 2013-2014
• MBBS (London) with Distinction in Biomedical Sciences, King’s College London School of Medicine, 2008  

• Singapore Country Representative, Asia-Pacific Regional Council, American Society of Clinical Oncology
• Chair, Lung Cancer Education Programme Committee, ASCO Annual Meeting 2027
• Chair, Locoregional Non-Small Cell Lung Cancer Programme Track, World Conference on Lung Cancer 2026
• Member, Global Multidisciplinary Practice Standards Committee, International Association for the Study of Lung Cancer
• Founding Board Member, Singapore Society of Neuro-Oncology
• Former Executive Board Member, Asian Society for Neuro-Oncology
• Medical Adviser, Brain Tumour Society Singapore
• Member, Scientific Committee, Lung Cancer Consortium Singapore
• Member, Asian Thoracic Oncology Research Group  

• Singapore Health Quality Service Award 2023 - Star, 2024
• ASCO Breakthrough Abstract Award, 2023
• Khoo Pilot Award (Collaborative), Principal Investigator, for research evaluating FET-PET in distinguishing tumour progression from pseudoprogression in high-grade gliomas, 2022
• Singapore Health Quality Service Award - Gold, 2022
• World Conference on Lung Cancer Early Career Education Award, 2022
• National Medical Research Council Clinician Scientist-Individual Research Grant New Investigator Grant, Principal Investigator, 2021
• SingHealth Publish! Award, 2021
• Conquer Cancer Foundation ASCO Merit Award, 2018
• Health Manpower Development Plan Fellowship Award, 2012
  

• Andratschke N, Antoni D, Chua KLM, et al. Cumulative lung dose-volume predictors of radiation pneumonitis in thoracic reirradiation: a systematic scoping review. Critical Reviews in Oncology/Hematology. 2026;222:105287.
• McMahon RA, Chua KLM, et al. Definitive radiotherapy to the primary tumor in stage IV non-small cell lung cancer: a consensus statement from the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee. Journal of Thoracic Oncology. 2026.
• Beddok A, Willmann J, Embring A, et al., Chua KLM. Reirradiation: standards, challenges and patient-focused strategies across tumour types. CA: A Cancer Journal for Clinicians. 2025.
• Said BI, Geng Y, Badiyan SN, et al., Chua KLM. Accelerated hypofractionated radiotherapy for locally advanced non-small cell lung cancer: a systematic review from the IASLC Advanced Radiation Technology Subcommittee. Journal of Thoracic Oncology. 2024;20:39-51.
• Huang CY, Jiang N, Shen M, et al., Chua KL. Oncogene-driven non-small cell lung cancers in patients with a history of smoking lack smoking-induced mutations. Cancer Research. 2024;84:2009-2020.
• Tan AC, Lai GGY, Saw SPL, Chua KLM, et al. Detection of circulating tumour DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer. Cancer. 2024;130:1758-1765.
• Horne A, Harada K, Brown KD, et al., Chua KLM. Treatment response biomarkers: working towards personalised radiotherapy for lung cancer. Journal of Thoracic Oncology. 2024;19:1164-1185.
• Hoo R, Chua KLM (co-first author), et al. Precision endpoints for contemporary precision oncology trials. Cancer Discovery. 2024;14:573-578.
• Bucknell NW, Belderbos J, Palma DA, et al., Chua KLM. Avoiding toxicity with lung radiation therapy: an IASLC perspective. Journal of Thoracic Oncology. 2022;17:961-973.
• Chua KLM, et al. Repurposing proton beam therapy through novel insights into tumour radioresistance. Clinical Oncology. 2021;33:e469-e481.
• Rulach R, Ball D, Chua KLM, et al. An international expert survey on the indications and practice of radical thoracic reirradiation for non-small cell lung cancer. Advances in Radiation Oncology. 2021;6:100653.
• Chua KLM, et al. High-dimensional characterization of the systemic immune landscape informs on synergism between radiotherapy and immune checkpoint blockade. International Journal of Radiation Oncology, Biology, Physics. 2020;108:70-80.
• Tan WL, Chua KLM (co-first author), et al. Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer. Journal of Thoracic Oncology. 2020;15:324-343.
• Glicksman RM, Tjong M, Neves-Junior WFP, et al., Chua KLM. Stereotactic ablative radiotherapy for the management of spinal metastases: a review and synthesis for the modern oncologist. JAMA Oncology. 2020;6:567-577.
• Chua KLM, et al. Intra- and inter-patient comparisons of DNA damage response biomarkers in nasopharynx cancer: analysis of the NCC0901 randomised controlled trial of induction chemotherapy in locally advanced nasopharynx cancer. BMC Cancer. 2018;18:1095.